afternoon, good Todd, Thanks, everyone. and
Total the revenue for $XX.X quarter the increase XX% XXXX, XXXX. million $X of level quarter XX% from was HTA the $X.X from the product million quarter the the total from total a the of fourth Minerva X% quarter was fourth the or Genesys XXXX. of fourth ES of increase revenue $X.X slightly was of of in At XXXX and over the and quarter quarter, XXXX. fourth of slightly the $X.X $X.X of quarter total revenue, or for million Symphion of $X in million, XXXX from third slightly XXXX, million XX% in fourth up up quarter million quarter XX% was down XXXX, of or million fourth fourth revenue in in of a
we of In in the general, product, a was revenue XXXX. atypical million, year by $XX.X much up was $XX.X revenue product Genesys we're in of the which Symphion, the XXXX, Genesys for year, in seeing million offset XXXX the XX% mature Total full X% revenue positive XX% trends total million XXXX, or Minerva from revenue is a flat from $XX.X in ES revenue. million At or more for as in from market total year of HTA in XXXX uterine share holding anatomies. full in from million total believe or for and XXXX. treatments decrease million down down in product HTA niche $XX.X $XX.X was And Minerva was Symphion XXXX, $XX.X $XX.X XX% level ES XXXX. million,
ES we're in very revenue disappointed decline, we're XXXX, were year-over-year as the build especially and experienced the we and momentum encouraged momentum to towards to overall Minerva with end working we relates hard XXXX. growth Symphion sales While sales the with the of it
fourth gross Our last a margin of XX.X% was XXXX decrease XX.X% reported of and quarter for of in the the the XX.X%, XXXX fourth margin gross reported quarter. quarter from
year full margin was the XXXX. the XXXX the XX.X% for from of margin gross XX.X%, year decrease a full for Gross
as Symphion, in lower the gross fixed impacted Our mix quarter as costs HTA increased margin margin our full the from product year an overall to which smaller ablation today current revenue base costs by over in well and macroeconomic gross fourth spread inflationary was has changing XXXX being Genesys product environment, a overhead profile. the away negatively
an impacting instrument. installed where expanding customer expense controllers base those is we on over future margin over is single-use offset by of the sites controllers recognize a of our sales of which period, placed the at handsets depreciation life gross Also time fixed the
of operating Total were the spending due reversal compared expense $X in research in acquisition-related milestone outreach, $X of payment of a operating litigation decrease force due final the reduction additional with $XX.X increase Boston the by and and liability XXXX partially The to expenses physician and for XXXX. as million a million marketing the spend. of to million expenses well to associated sales driven $XX.X was period was same million by the $X matters, fourth in and This on the patient Scientific. an in development-related million sales increased reserve expansion offset quarter as
was $X.X Noncash quarter expense operating approximately in the Noncash the XXXX. included of million million fourth in fourth depreciation was fourth from and versus expenses the unchanged operating of fourth million total $X.X in in of $X.X expenses quarter amortization XXXX. of included expense in XXXX, stock-based quarter quarter XXXX compensation the
to administrative $X.X in milestone of of $X.X the Total was well on with compared year the patient $XX.X were for litigation million company a acquisition-related final the outreach, of and due full for and operating $X Scientific. The and XXXX reserve an million expenses in matters, increase by Boston reduction payment XXXX. as in marketing to partially and the the the by for for increase operating expansion million million as sales XXXX the million associated throughout due physician reversal was as general public operating increased liability of offset associated year expense force decrease sales full driven XXXX. the a expenses spending an $XX.X expenses to year full with This
XXXX. expenses $X.X included $X.X amortization total versus in XXXX. full compensation was approximately from Noncash operating the was year depreciation the year and XXXX included million XXXX, operating unchanged expense in million stock-based full for $X.X expenses expense in million Noncash for
The result loss quarter the XXXX the Our embedded debt. with following of of for the fourth fourth liabilities compared was to quarter our in derivative the of reported to income of debt of XXXX. the of net the reversal in income the equity previous million of XXXX quarter liabilities net of reported conversion third-party primarily XXXX $X.X fourth a refinancing the our and onetime million of fourth of was the IPO as quarter net result in $XX.X derivative extinguishment of
XXXX, negative full $X.X a On for XXXX. was in a for $X.X non-GAAP $XX.X the $XX.X to compared XXXX. of basis, for the million million $XX.X the year year For reported loss was of XXXX the million net full million loss our EBITDA quarter full million in we've net Adjusted compared negative of to year for EBITDA of reported adjusted negative $XX.X adjusted adjusted for compared quarter to fourth XXXX. EBITDA fourth XXXX million EBITDA negative the
amortization balance XXXX acquisition As May finished expense. From as a In significant cash related cash. unrestricted cash, was we expenses changes in intangibles the of reminder, Resectr as perspective, in Symphion sheet the in we total, quarter significant the quarter million. the outflow compensation million $X.X a XXXX, our and well to of excluding assets, have fourth noncash with restricted $X.X noncash HTA, from stock-based the Genesys
long-term Our debt following our and the the XXXX of facility. from long-term unchanged substantially previous of fourth refinancing were IPO quarter our liabilities
development common million $XX interest-only Partners, X, allowing And of excited have amortization this Associates. our a intend Accelmed as a rolls the purposes. of further advance growth. of led recent debt after quarter proceeds in year cash we February support our corporate closed mission. Accelmed support highlight our placement third the which We existing an as XXXX, and And it company new net schedule. and research working by a with together investor and a year $XX and capital extended facility from stock to also financing, from general New for activities Enterprise million our our financing. furthering our to three to cash the investments, wanted into reminder, long-term On which equity this operations investor included existing We're private our chapter we have financing the with through very use runway, enter is to to I
with well recent increased on annual at our our call earnings CEO. look contracts customer updating plan that a continued we XXXX forward following of progress of business financing, first controllers fully discuss full positioned review growth. future organization, for our growing on signing We are in completion sites, guidance We and of line to calls. drive May, a quarter new emphasis installed we of products to on our Board revenue our staffed strategic you our to sales With believe base and future
and back say you operator. With to that, I'll thank turn call the the
